Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs
- PMID: 14613859
- DOI: 10.1016/s0008-6363(03)00543-1
Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs
Abstract
Objectives: AVE0118 is a novel blocker of the K(+) channels K(v)1.5 and K(v)4.3 which are the molecular basis for the human cardiac ultrarapid delayed rectifier potassium current (I(Kur)) and the transient outward current (I(to)). The objective of this study was to investigate the effect of AVE0118 on atrial refractoriness (ERP), left atrial vulnerability (LAV) and on left atrial monophasic action potentials (MAP) in pentobarbital anesthetized pigs in comparison to the selective I(Kr) blocker dofetilide in order to assess the therapeutic potential of the novel K(+) channel blocker for atrial fibrillation.
Methods: Atrial ERP was determined with the S1-S2-stimulus method in the free walls of left and right atrium at 240, 300 and 400 ms basic cycle length (BCL). The inducibility of mostly nonsustained atrial tachyarrhythmias by the premature S2 extrastimulus, which is very high in the left pig atrium and referred to as LAV, was evaluated before and after drugs. Left atrial epicardial MAP was recorded to study the influence of the potassium channel blockers on the time course of repolarization. Left ventricular epicardial MAP, ERP and QT interval were measured to investigate a possible effect of AVE0118 on ventricular repolarization.
Results: ERPs determined at 240, 300 and 400 ms BCL were significantly shorter in the left vs. right atrium (99+/-3, 106+/-4 and 113+/-3 ms vs. 133+/-4 ms, 142+/-4 and 149+/-5, respectively; p<0.001; n=21). AVE0118 administered i.v. dose-dependently prolonged the atrial ERP independent from rate and inhibited LAV (100% at 0.5 and 1 mg/kg) while having no effect at all on the corrected QT (QTc) interval. At 1 mg/kg (n=5) AVE0118 prolonged left vs. right atrial ERP by 49.6+/-4.1 ms vs. 37.7+/-9.7 ms (means+/-SEM of changes at 240, 300, and 400 ms BCL), respectively, corresponding to a relative increase of 53.2+/-6.2% vs. 27.6+/-6.8% (p<0.05 for percent increase of left vs. right atrial ERP). In a separate group of pigs (n=5) AVE0118 had no effect on left ventricular ERP at 333, 400 and 500 ms BCL and no effect on MAP duration and QT at 600 ms BCL. After 1 mg/kg of AVE0118 the atrial MAP was significantly prolonged already at 10% repolarization (P<0.05; n=7) reaching the maximum at 40% repolarization. In contrast to AVE0118 the effect of dofetilide (10 microg/kg) on atrial MAP started to become significant only at 60% repolarization (n=6) with a maximum increase at 90%. Dofetilide, which prolonged the QTc interval by 16.9% (P<0.001), had a significantly stronger effect on right (34.7+/-5 ms) vs. left atrial ERP (23.5+/-7 ms) at 300 ms BCL, respectively, but did not significantly inhibit LAV (14%; n=6).
Conclusion: The novel K(+) channel blocker AVE0118 prolonged atrial ERP and showed strong atrial antiarrhythmic efficacy with no apparent effect on ventricular repolarization in pigs in vivo.
Similar articles
-
Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.Naunyn Schmiedebergs Arch Pharmacol. 2002 Nov;366(5):482-7. doi: 10.1007/s00210-002-0599-x. Epub 2002 Sep 5. Naunyn Schmiedebergs Arch Pharmacol. 2002. PMID: 12382079
-
"Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat.Circulation. 2004 Sep 28;110(13):1717-24. doi: 10.1161/01.CIR.0000143050.22291.2E. Epub 2004 Sep 13. Circulation. 2004. PMID: 15364815
-
Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.Med Sci Monit. 2004 Jul;10(7):BR221-8. Epub 2004 Jun 29. Med Sci Monit. 2004. PMID: 15232496
-
Theoretical possibilities for the development of novel antiarrhythmic drugs.Curr Med Chem. 2004 Jan;11(1):1-11. doi: 10.2174/0929867043456296. Curr Med Chem. 2004. PMID: 14754422 Review.
-
Molecular biology of the long QT syndrome: impact on management.Pacing Clin Electrophysiol. 1997 Aug;20(8 Pt 2):2052-7. doi: 10.1111/j.1540-8159.1997.tb03626.x. Pacing Clin Electrophysiol. 1997. PMID: 9272507 Review.
Cited by
-
New Strategies for the Treatment of Atrial Fibrillation.Pharmaceuticals (Basel). 2021 Sep 15;14(9):926. doi: 10.3390/ph14090926. Pharmaceuticals (Basel). 2021. PMID: 34577626 Free PMC article. Review.
-
Breathing Stimulant Compounds Inhibit TASK-3 Potassium Channel Function Likely by Binding at a Common Site in the Channel Pore.Mol Pharmacol. 2015 Nov;88(5):926-34. doi: 10.1124/mol.115.100107. Epub 2015 Aug 12. Mol Pharmacol. 2015. PMID: 26268529 Free PMC article.
-
Voltage-gated potassium channels as therapeutic targets.Nat Rev Drug Discov. 2009 Dec;8(12):982-1001. doi: 10.1038/nrd2983. Nat Rev Drug Discov. 2009. PMID: 19949402 Free PMC article. Review.
-
Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action.Naunyn Schmiedebergs Arch Pharmacol. 2013 Nov;386(11):991-9. doi: 10.1007/s00210-013-0901-0. Epub 2013 Jul 6. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23832378
-
Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies.Curr Issues Mol Biol. 2025 Jul 17;47(7):559. doi: 10.3390/cimb47070559. Curr Issues Mol Biol. 2025. PMID: 40729028 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical